Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefiti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncol Lett
Главные авторы: Hirai, Fumihiko, Edagawa, Makoto, Shimamatsu, Shinichiro, Toyozawa, Ryo, Toyokawa, Gouji, Nosaki, Kaname, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro, Ichinose, Yukito
Формат: Artigo
Язык:Inglês
Опубликовано: D.A. Spandidos 2017
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494899/
https://ncbi.nlm.nih.gov/pubmed/28693169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6118
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы